2015 American Transplant Congress
A New Diagnostic Tool for Antibody Mediated Rejection in Heart and Lung Transplantation: Intragraft Donor Specific Anti-HLA Antibodies Detection
INTRODUCTION: Antibody mediated rejection (AMR) is one of the causes of dysfunction and graft loss. The limited histological features, with a weak sensibility of c4d,…2015 American Transplant Congress
The Impact of a Desensitization Protocol Using Plasmapheresis and Intravenous Immunoglobulin On Graft Outcome in Kidney Recipients With Donor Specific Anti-HLA Antibodies
Hospital Geral de Fortaleza, Fortaleza, Brazil.
Introduction: Kidney transplantation in patients with donor-specific anti-HLA antibodies (DSA) has been associated with a worse prognosis. The high cost, infectious complications and conflicting results…2015 American Transplant Congress
Pre-Transplant Donor Specific Antibody With Negative Flow-Crossmatch Was Related to Higher Acute Rejection But Not to Poor Graft Survival
Background: DSA have been associated to lower graft survival and a higher humoral rejection rate, but there is a concern about the clinical impact of…2015 American Transplant Congress
High-Resolution Perfusion Mapping to Detect Heart Transplant Rejection Using Contrast Enhance Ultrasound
Background: One of the key unmet needs in heart transplantation is an effective and accurate, non-invasive tool to diagnose acute and chronic heart transplant rejection.…2015 American Transplant Congress
Improving ABMR Diagnostics Through Advanced Anti-HLA Antibody Screening Techniques
The identification of low-level antibodies by single antigen bead methodology has brought advancements in risk evaluation of kidney transplants recipients. However, the use of the…2015 American Transplant Congress
Cyclophosphamide as a Salvage Therapy for Combined Intravenous Immunoglobulins and Plasmapheresis Refractory Antibody-Mediated Rejection
Acute antibody-mediated rejection (AMR) poses a significant risk to graft survival. Current or standard treatment (ST) of AMR currently consists of plasmapheresis (PP), intravenous immunoglobulin…2015 American Transplant Congress
Early Vs. Late Acute Antibody Mediated Rejection Among Renal Transplant Recipients in Terms of Its Response to Rituximab Therapy-Single Center Expereince
Nephrology, OTC of Kuwait, kuwait, Kuwait.
IntroductionThere are no comparable trials concerning the use of rituximab among renal transplant recipients with acute antibody mediated rejection.Aim of the study:We aimed to compare…2015 American Transplant Congress
Marrow Mesenchymal Stem Cells Attenuate Immune Rejection in Murine Lung Allograft
Objectives:The inherent immunosuppressive properties and low immunogenicity of mesenchymal stems cells (MSCs) suggested their therapeutic potential in transplantation. In this study we investigated if systematic…2015 American Transplant Congress
The Association Between Donor & Recipient Gene Variants and Tacrolimus Safety & Efficacy in a Diverse Cohort of Kidney Transplant Recipients
Medical University of South Carolina, Charleston, SC.
Previous studies have associated donor P-glycoprotein (PGP) gene variants (ABCB1) with risk of developing CNI-toxicity, while also establishing recipient CYP3A5*1 and ABCB1 gene variants are…2015 American Transplant Congress
Inadequate Overall Immunosuppression Is a Risk for Late Acute Rejection Despite Alemtuzumab Induction in Simultaneous Pancreas Kidney Transplant Recipients
Introduction: Simultaneous pancreas-kidney transplantation (SPK) has become the treatment of choice for patients with end-stage renal disease due to Type 1 Diabetes Mellitus. SPK is…
- « Previous Page
- 1
- …
- 152
- 153
- 154
- 155
- 156
- …
- 172
- Next Page »